Loading
Loading
Growth Hormone & Secretagogues · 3mg
Janoshik-tested · 10 vials per kit
Hexarelin is a synthetic hexapeptide growth hormone secretagogue studied in preclinical research as one of the most potent GHRP compounds. Research has examined its potential to strongly stimulate GH release via ghrelin receptors, support IGF-1 production, and exhibit independent cardioprotective effects through CD36 receptor interaction. Studies have explored applications in GH deficiency and cardiac protection models.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
Hexarelin
Examorelin
Hexarelin (Examorelin, EP-23905) is a synthetic hexapeptide GHS-R1a agonist and among the most potent GH secretagogues in the GHRP family on a per-dose basis. Developed by Mediolanum Farmaceutici in the 1990s, its extraordinary potency is partially offset by receptor downregulation with repeated dosing — desensitisation develops more rapidly than with Ipamorelin or GHRP-2.
Hexarelin activates GHS-R1a with the highest intrinsic efficacy of the GHRP class, producing very large acute GH pulses. Unique to Hexarelin within the GHS-R1a agonist class, it also has direct cardiovascular activity at CD36 (scavenger receptor class B member 3) expressed on cardiomyocytes — effects completely independent of GH secretion and potentially relevant to cardiac protection in ischaemia. Cortisol and prolactin stimulation is intermediate between GHRP-6 and Ipamorelin.
Acute GH pulse protocols, GH secretagogue pharmacology, cardiac protection research (Hexarelin has demonstrated cardioprotective effects in ischaemia-reperfusion models independent of GH axis via CD36), body composition, and post-infarction cardiac recovery models. Its direct cardiac receptor activity makes it uniquely positioned for cardiology-adjacent peptide research.
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
